Diuretic therapy in acute decompensated heart failure – Bolus or continuous?  by Jariwala, Pankaj & Koduganti, Saratchandra
ww.sciencedirect.com
i n d i a n h e a r t j o u rn a l 6 6 ( 2 0 1 4 ) 3 1 7e3 1 9Available online at wScienceDirect
journal homepage: www.elsevier .com/locate/ ih jEditorialDiuretic therapy in acute decompensated heart
failure e Bolus or continuous?Pankaj Jariwala*, Saratchandra Koduganti
Indo US Superspeciality Hospitals, Shyam Karan Road, Ameer Pet, Hyderabad 500016, IndiaThe combination of aging of the population and improved
survival after myocardial infarction has created a rapid rise in
the number of patients currently living with chronic heart
failure, with a consequent increase in the number of hospi-
talizations for acute decompensated heart failure.
Congestion and volume overload are the hallmarks of
acute decompensated heart failure (ADHF), and loop diuretics
have historically been the cornerstone of the therapy. Diuretic
therapy is the standard treatment in emergency rooms and in
the cardiac intensive care units. Loop diuretics in the form of
bolus doses are given for the symptomatic relief of acute onset
of breathlessness. In patients with pulmonary edema, fluid
restriction and diuretic therapy have been shown to promote
a faster resolution of symptoms and clinical improvement,
and have also been associated with a decrease in the duration
of stay in the intensive care unit.1
Among the loop diuretics, Furosemide and Torsemide are
the most commonly used for the management of acute
decompensated heart failure. They result in brisk diuresis and
the property of mild peripheral venodilation helps in further
reduction of preload. Hence, they relieve symptom of breath-
lessness inpatientswithvolumeoverloadpresentingasADHF.2
Their mode of administration is either as bolus doses or
continuous infusion. Several reports have suggested that
continuous intravenous administration of loop diuretics may
be superior to intermittent administration.3 Till today, we do
not have a consensus about the mode of administration of
diuretic treatment in these patients. There are many small
observational studies comparing bolus doses with continuous
infusion of diuretics in ADHF management. They had con-
flicting results. Aziz et al evaluated 116 patients retrospec-
tively and divided them into two groups: Group A patients
received furosemide by continuous infusion combined with
low-dose dopamine infusion. Group B patients received bolus* Corresponding author. Department of Cardiology, Indo US Superspec
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tion and re-admission rate was recorded.3 They concluded
that continuous infusion of furosemide in addition to low-
dose dopamine is safe, effective and less nephrotoxic than
intermittent boluses in patients admitted with acute decom-
pensated heart failure and associated with shorter hospital
stay with lower readmission rates at 30 days.
One study that deserves to be specificallymentioned in this
context is the DOSE study by Felkar et al In this trial, they
compared bolus versus infusion and high dose versus low
dose of furosemide. There was no difference in the net fluid
loss at 72 h in bolus versus continuous infusion arms, but high
dose group had greater diuresis than low dose group. As per
the DOSE study, among patients with acute decompensated
heart failure, there were no significant differences in patients'
global assessment of symptoms or in the change in renal
function when diuretic therapy was administered by bolus as
compared with continuous infusion or at a high dose as
compared with a low dose.4 Those who have severe breath-
lessness have better symptom relief by higher intravenous
intermittent bolus doses. As per the results of DOSE study,
higher doses of diuretics may offer clinical advantages in
terms of greater diuresis, weight loss, and relief of dyspnea,
without any identified long-term disadvantages.4
Some of the trials and meta-analyses which are listed in
Table 1, did not show any consensus about the use of diuretic
therapy and its mode of administration.
In their meta-analysis, Amer et al have concluded that
furosemide given as a continuous infusion leads to greater
diuresis and reduction in bodyweight in pts admitted for ADHF
compared to bolus doses. Urinary Sodium excretion and dura-
tion of hospital stay did not differ between the two groups.13
In this issue of the Indian heart journal, Shah et al have
presented their elegantly conducted study of comparison ofiality Hospitals, Shyam Karan Road, Ameer Pet, Hyderabad 500016,
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Table 1 e Randomized Trials of Bolus Versus Continuous Infusion of Diuretics in Heart Failure Study [Updated table adapted with permission from Felker GM, O'Connor
CM, Braunwald E. Circ Heart Fail. 2009 Jan; 2(1):56e62.].
Study No. of patients Design Intervention Duration Endpoints Findings
User at al5 8 Randomized, cross-over,
unblinded
Continuous infusion vs BID IV bolus 24 h Urine output Bolus better
Dormans et al6 20 Randomized, cross-over,
unblinded
Continuous infusion vs single IV Bolus 24 h Urine output Infusion better
Kramer et al7 8 Randomized, cross-over,
unblinded
Continuous infusion vs single IV
24 h Bolus
24 h Urine output No difference
Lahav et al8 9 Randomized, cross-over,
unblinded
Continuous infusion vs Q8 bolus 48 h Urine output Infusion better
Licata et al9 107 Randomized, single blind Continuous infusion þ hypertonic
saline vs Q12 bolus
6-12 days Urine output at 24 h & Mortality Infusion better on all end points
Bivouac et al10 20 Randomized, single blind,
crossover
Q12 4-h infusion vs Q12 bolus 24 h Urine output Infusion better
Schuller et al11 33 Randomized, unblinded Continuous infusion vs bolus IV BID 72 h Mortality No difference
Shah et al12 308 2  2 factorial design
Randomized clinical trial
Continuous infusion bolus IV BID 24 h Symptom relief, renal function,
net fluid loss, or death and
rehospitalization at 60 days
Patients on higher diuretic doses
have greater disease severity,
and may benefit from an initial
bolus strategy
Aziz et al3 116 Retrospective analysis Continuous infusion combined with
low-dose dopamine infusion vs. bolus
therapy
48 h Nephrotoxicity, determined by
the rise in blood urea nitrogen and
creatinine levels, and readmission
rates for heart failure decompensation
at a 30-day follow up. Delta weight
change, length of hospital stay, and
all cause mortality at 90 days
Continuous infusion of furosemide
in addition to low-dose dopamine
is safe, effective and less nephrotoxic
than intermittent boluses. It has a
shorter hospital stay and lower
readmission rates at 30 days
Amer et al13 564 Meta-analysis Continuous infusion vs. intermittent
bolus
24 h Urine output, reduction in total body
weight
Continuous infusion for greater
diuresis and reduction in total
body weight in patients hospitalized
with ADHF
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dopamine vs. intravenous furosemide bolus in two divided
doses vs. intravenous furosemide continuous infusionalone.14
Their primary endpoint was a negative fluid balance at 24 h
after admission. Secondary end points were duration of hos-
pital stay, negative fluid balance at 48, 72,96 h, the trend of
serum electrolytes, and renal function and 30 day clinical
outcome (death and emergency department visits). Overall,
ninety patientswere included in the study. Therewas a greater
diuresis in the first 24 h and a shorter hospital stay with the
bolus group. There was no significant difference in renal
function and serum sodium and serum potassium levels.
There was no difference in the number of emergency depart-
ment visits among the three groups.
They concluded that all three modes of diuretic therapies
can be practiced with no difference in worsening of renal
function and electrolyte levels. Bolus dose administration
with its rapid volume loss and shorter hospital staymight be a
more effective diuretic strategy in a resource limited setting of
ours, one wishes that they performed the study on greater
number of patients. The impact of different strategies on BNP
could have been studied.
It is obvious from the above studies that there is no clear
consensus on how to administer diuretics during ADHF. One
has to use one’ own experience, individual patient's clinical
status, degree of fluid overload, baseline renal parameters,
electrolyte status and also monitor closely BNP, serum creat-
inine and electrolytes during treatment.
The standard justification for the use of continuous infusion
of loop diuretics is to avoid the so called “diuretic resistance”.
Actually, there is no properly described term as “diuretic resis-
tance”. It is used when the patients are unable to meet their
clinically required decongestive targets despite large doses of
loop diuretics.15 The pharmacokinetic and pharmacodynamic
causes of diuretic resistance are delayed absorption of the
diuretic, reducedsecretionof thediuretic into the tubular lumen
(its site of action), compensatory retention of sodium after the
effectiveperiodof thediureticandhypertrophyandhyperplasia
of epithelial cells of the distal convoluted tubule.16 Also drug
resistance develops frequentlywith repeated administration of
loop diuretics and, as a consequence, fluid retention and
congestion recur. Loop diuretic resistance is likely to be due to
theoperationofseveralcounter-regulatoryprocesses, including
renin angiotensin system (RAAS) which cause fluid retention.2
Apart from a continuous infusion of a loop diuretic, the
diuretic resistance can be overcome by increasing doses of
loop diuretics, use of more potent diuretics like Bumetanide,
Torsemide; or a combination of diuretics from different clas-
ses such as metolazone or thiazide diuretics.16
Combining loop and thiazide diuretics in patients with CHF
and diuretic resistance is a very elegant and logical treatment
option because it takes into account the pathophysiological
mechanism.15,16
The indiscriminate use of diuretics not only carries the risk
of over-diuresis referred above, but is also related to detri-
mental effects on renal function, particularly among elderly
patients. Even without over-diuresis, high doses of diuretics
with concomitant worsening renal function have been tied to
both longer hospital length of stay and increased mortality
after discharge.15Every intensive care unit should have its own protocol
regarding the use of diuretic therapy designed in consultation
with intensivist, Cardiologist and Nephrologist and based on
the evidence available in the literature. This strategy will
prevent overdosing the patients with diuretics.r e f e r e n c e s
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